PMCF and PMS Documentation Translation for MDR Post-Market

PMCF translation is the specialised translation of post-market clinical follow-up documentation, including PMCF plans, PMCF evaluation reports, surveys, registry inputs and clinical follow-up data, into target languages required by the markets where a medical device is placed. Under the MDR, PMCF activities support ongoing clinical evidence throughout the device lifecycle and feed CER updates. Translations must accurately reflect approved source content, with controlled clinical terminology and consistency with surrounding regulatory documentation. AbroadLink delivers PMCF translation with qualified medical linguists, ISO-based processes and risk-based workflow selection tailored to device class and document type.

PMS documentation translation covers post-market surveillance documents such as PMS plans, PMS reports, summaries, trend analyses and supporting evidence used to monitor a medical device's safety and performance after market launch. Under the MDR, PMS is an ongoing activity feeding CER updates, vigilance flows and benefit-risk reassessment. Multilingual content must accurately reflect approved source material with controlled medical device terminology and version alignment to CERs, SSCPs and related documentation. AbroadLink supports PMS documentation translation with qualified medical linguists, terminology control and risk-based workflow selection appropriate to the content.

Post-market surveillance translation is the multilingual translation of the documentation generated by a manufacturer's MDR post-market surveillance system. It typically includes PMS plans, PMS reports, PSURs, complaint summaries, trend analyses, vigilance correspondence and supporting evidence used to monitor safety, performance and benefit-risk after market launch. Translated content supports local affiliates, distributors, competent authorities and notified bodies across EU and international markets. AbroadLink delivers post-market surveillance translation with qualified medical linguists, controlled terminology, ISO-based processes and risk-based workflow selection appropriate to the document type, evidence sensitivity and audience.

PMCF / PMS translation workflows may cover PMCF plans, PMCF evaluation reports, PMCF surveys, registry content, PMS plans, PMS reports, PSURs, periodic safety updates, complaint summaries, incident reports, vigilance correspondence, trend analyses, CAPA inputs feeding post-market files and supporting evidence updates. They may also extend to CER inputs, SSCP updates, IFU revisions and labelling changes triggered by post-market findings. The exact scope depends on device class, regulatory pathway and the manufacturer's post-market strategy. AbroadLink scopes each project around the documents actually involved and applies risk-based workflow selection per document type and sensitivity.

No. This is central to our risk-based approach. The accuracy objective for PMCF translation and PMS documentation translation does not change with device class, document length or workflow choice. Lower-risk workflows apply leaner review steps to content where translation risk is lower, such as some supporting or administrative sections, while still aiming for accurate, complete, source-faithful translation. Higher-risk workflows add independent revision under ISO 17100 and other controls to reduce the probability and consequences of translation error in PMCF reports, PMS conclusions, PSURs, vigilance wording and notified-body-facing post-market content. Accuracy stays the constant objective.

AI can support PMCF and PMS documentation translation only as a controlled pre-translation step inside a workflow with qualified human review. Through aiHubLink, AbroadLink connects generative AI models with client terminology and previous approved translations, then applies medical-linguist review under ISO-based processes. For PMCF reports, PMS conclusions, PSURs, vigilance content, complaint summaries and trend analyses, AI output is always treated as a draft, not a finished post-market document. The client remains responsible for clinical, regulatory, vigilance, quality and post-market approval decisions. AI is positioned cautiously: useful where suitable, never a substitute for qualified human review.

No. Translation is one input into a broader post-market surveillance and conformity assessment process. AbroadLink delivers accurate PMCF and PMS translation, applies risk-based workflows, uses controlled medical device terminology, provides traceable certificates through CertLink and supports your QMS with documented processes. However, the manufacturer remains responsible for post-market surveillance, PMCF strategy, PMS adequacy, post-market evidence sufficiency, vigilance reporting, notified body communication and final compliance decisions. PMCF translation, PMS documentation translation and post-market surveillance translation are language-side contributions to your post-market system, not substitutes for clinical, regulatory, vigilance or product activities.

CertLink is AbroadLink's portal for accessing translation certificates linked to each project. For PMCF translation, PMS documentation translation, post-market surveillance translation and post-market clinical follow-up translation, certificates record translator and reviewer identification, project codes, document references and processes applied. PMS Managers, PMCF Managers and Vigilance Managers can search and download certificates as audit-ready evidence supporting QMS records, technical files, internal audits, notified body interactions and competent authority requests. CertLink does not replace post-market evidence validation, PMS adequacy or notified body acceptance, which remain outside AbroadLink's scope. It provides traceable language-side evidence that complements your existing documentation.